Risk factors for the leakage of chemotherapeutic agents into systemic circulation after transcatheter arterial chemoembolization of hepatocellular carcinoma

Kaohsiung Journal of Medical Sciences

Volumn 27, Issue 10, 2011, Pages 431-436

  Hsieh, Ming Yen ^a   Lin, Zu Yau ^b,c   Chen, Su Hwei ^d   Chuang, Wan Long ^b,c  

^a KAOHSIUNG MUNICIPAL TA TUNG HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Epirubicin; Hepatocellular carcinoma; Mitomycin C; Plasma concentration; Transcatheter arterial chemoembolization

Indexed keywords

EPIRUBICIN; IODINATED POPPYSEED OIL; MITOMYCIN C;

ADULT; AGED; ARTICLE; CHEMOEMBOLIZATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG TOLERABILITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; RISK FACTOR; SYSTEMIC CIRCULATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, HEPATOCELLULAR; CATHETERIZATION; CHEMOEMBOLIZATION, THERAPEUTIC; EPIRUBICIN; ETHIODIZED OIL; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM GRADING; PROSPECTIVE STUDIES; RISK FACTORS; TAIWAN;

EID: 80053053709     PISSN: 1607551X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.kjms.2011.06.001     Document Type: Article

References (21)

1. B. Acunas, and I. Rozanes Hepatocellular carcinoma: treatment with transcatheter arterial chemoembolization Eur J Radiol 32 1999 86 89 (Pubitemid 29505305)
2. S.A. Hussain, D.R. Ferry, G. El-Gazzaz, D.F. Mirza, N.D. James, and P. McMaster Hepatocellular carcinoma Ann Oncol 12 2001 161 172 (Pubitemid 32223862)
3. L. Marelli, R. Stigliano, C. Triantos, M. Senzolo, E. Cholongitas, and N. Davies Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies Cardiovasc Intervent Radiol 30 2007 6 25 (Pubitemid 44900485)
4. D.B. Brown, T.K. Pilgram, M.D. Darcy, C.E. Fundakowski, M. Lisker-Melman, and W.C. Chapman Hepatic arterial chemoembolization for hepatocellular carcinoma: comparison of survival rates with different embolic agents J Vasc Interv Radiol 16 2005 1661 1666 (Pubitemid 44431163)
5. M. Pleguezuelo, L. Marelli, M. Misseri, G. Germani, V. Calvaruso, and E. Xiruochakis TACE versus TAE as therapy for hepatocellular carcinoma Expert Rev Anticancer Ther 8 2008 1623 1641
6. S. Kobayashi, Y. Narimatsu, K. Ogawa, S. Hashimoto, S. Nakatsuka, and H. Miura Transcatheter hepatic arterial chemoembolization using epirubicin-lipiodol: experimental and pharmacological evaluation Cancer Chemother Pharmacol 31 Suppl 1992 S45 S50
7. H.M. Dodds, E.T. Walpole, L.P. Rivory, R.W. Strong, and S.M. Pond Disposition of epirubicin after intraarterial administration in Lipiodol to patients with hepatocellular carcinoma Ther Drug Monit 18 1996 537 543 (Pubitemid 26330473)
8. J.W. Ding, Z.D. Wu, R. Andersson, and S. Bengmark Pharmacokinetics of mitomycin C following hepatic arterial chemoembolization with gelfoam HPB Surg 5 1992 161 169
9. A.F. Rump, U. Woschée, M. Theisohn, R. Fischbach, W. Heindel, and K. Lackner Pharmacokinetics of intra-arterial mitomycin C in the chemoembolization treatment of liver metastases with polyvinylalcohol or degradable starch microspheres Eur J Clin Pharmacol 58 2002 459 465 (Pubitemid 35244919)
10. A.F. Rump, S. Botvinik-Helling, M. Theisohn, W. Biederbick, J.M. Schierholz, and M. Stemmler Pharmacokinetics of intraarterial mitomycin C in the chemoembolisation treatment of liver metastases Gen Pharmacol 27 1996 669 671 (Pubitemid 26233340)
11. K. Schutte, J. Bornschein, and P. Malfertheiner Hepatocellular carcinoma-epidemiological trends and risk factors Dig Dis 27 2009 80 92
12. J.N. Cormier, K.T. Thomas, R.S. Chari, and C.W. Pinson Management of hepatocellular carcinoma J Gastrointest Surg 10 2006 761 780 (Pubitemid 43711147)
13. S. Vento, F. Cainelli, and M.S. Longhi Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue Lancet Oncol 3 2002 333 340 (Pubitemid 34661982)
14. H. Nagamatsu, R. Kumashiro, S. Itano, S. Matsugaki, and M. Sata Investigation of associating factors in exacerbation of liver damage after chemotherapy in patients with HBV-related HCC Hepatol Res 26 2003 293 301 (Pubitemid 37184518)
15. J.W. Jang, J.Y. Choi, S.H. Bae, C.W. Kim, S.K. Yoon, and S.H. Cho Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma J Hepatol 41 2004 427 435 (Pubitemid 39158752)
16. J. Ahmad, J. Rhee, and B.I. Carr The effects of hepatic artery chemotherapy on viral hepatitis in patients with hepatocellular carcinoma Dig Dis Sci 50 2005 331 335 (Pubitemid 40311543)
17. J.W. Park, K.W. Park, S.H. Cho, H.S. Park, W.J. Lee, and D.H. Lee Risk of hepatitis B exacerbation is low after transcatheter arterial chemoembolization therapy for patients with HBV-related hepatocellular carcinoma: report of a prospective study Am J Gastroenterol 100 2005 2194 2200
18. J. Xu, Y.H. Wang, J.L. Xia, N.L. Ge, Y. Chen, and S.L. Ye Effect of transcatheter arterial chemoembolization on HBV DNA level in primary liver cancer patients Ai Zheng 28 2009 520 523 [in Chinese]
19. Z.Y. Lin, L.Y. Wang, J.H. Wang, S.N. Lu, S.C. Chen, and W.L. Chuang Clinical utility of color Doppler sonography in the differentiation of hepatocellular carcinoma from metastases and hemangioma J Ultrasound Med 16 1997 51 58
20. G. Poggi, P. Quaretti, C. Minoia, G. Bernardo, M.R. Bonora, and R. Gaggeri Transhepatic arterial chemoembolization with oxaliplatin-eluting microspheres (OEM-TACE) for unresectable hepatic tumors Anticancer Res 28 2008 3835 3842
21. J.I. Bilbao, E. de Luis, J.A. García de Jalón, A. de Martino, M.D. Lozano, and A.M. de la Cuesta Comparative study of four different spherical embolic particles in an animal model: a morphologic and histologic evaluation J Vasc Interv Radiol 19 2008 1625 1638